# A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

> **NCT05806099** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** MBS303

## Key facts

- **NCT ID:** NCT05806099
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-28
- **Primary completion:** 2025-11
- **Final completion:** 2026-11
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806099, "A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05806099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*